Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Si Yang Li, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Paul J. Converse, Khisimuzi Mdluli, Eric Nuermberger

Research output: Contribution to journalArticle

Abstract

New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus PZA shortened the treatment duration necessary to prevent relapse by 2 to 3 months and 1 to 2 months, respectively, compared with the current first-line regimen, in a murine TB model. These 3-drug combinations are now being studied in clinical trials. Here, the 4-drug combination of BDQPMDMXFPZA was compared to its 3-drug component regimens and different treatment durations of PZA and MXF were explored, to identify the optimal regimens and treatment times and to estimate the likelihood of success against drug-resistant strains. BDQPMDMXFPZA rendered all mice relapse-free after 2 months of treatment. PZA administration could be discontinued after the first month of treatment without worsening outcomes, whereas the absence of MXF, PZA, or BDQ administration from the beginning necessitated approximately 0.5, 1, or 2 months, respectively, of additional treatment to attain the same outcome.

Original languageEnglish (US)
Article numbere00913-17
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

bedaquiline
Pyrazinamide
Tuberculosis
Drug Combinations
Recurrence
Multidrug-Resistant Tuberculosis
Pharmaceutical Preparations
moxifloxacin
2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine
Clinical Trials

Keywords

  • Bedaquliine
  • Mouse
  • Moxifloxacin
  • Mycobacterium tuberculosis
  • Pretomanid
  • Pyrazinamide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. / Li, Si Yang; Tasneen, Rokeya; Tyagi, Sandeep; Soni, Heena; Converse, Paul J.; Mdluli, Khisimuzi; Nuermberger, Eric.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 9, e00913-17, 01.09.2017.

Research output: Contribution to journalArticle

@article{d238b65b617e44f0b2955566db7f64bf,
title = "Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis",
abstract = "New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus PZA shortened the treatment duration necessary to prevent relapse by 2 to 3 months and 1 to 2 months, respectively, compared with the current first-line regimen, in a murine TB model. These 3-drug combinations are now being studied in clinical trials. Here, the 4-drug combination of BDQPMDMXFPZA was compared to its 3-drug component regimens and different treatment durations of PZA and MXF were explored, to identify the optimal regimens and treatment times and to estimate the likelihood of success against drug-resistant strains. BDQPMDMXFPZA rendered all mice relapse-free after 2 months of treatment. PZA administration could be discontinued after the first month of treatment without worsening outcomes, whereas the absence of MXF, PZA, or BDQ administration from the beginning necessitated approximately 0.5, 1, or 2 months, respectively, of additional treatment to attain the same outcome.",
keywords = "Bedaquliine, Mouse, Moxifloxacin, Mycobacterium tuberculosis, Pretomanid, Pyrazinamide",
author = "Li, {Si Yang} and Rokeya Tasneen and Sandeep Tyagi and Heena Soni and Converse, {Paul J.} and Khisimuzi Mdluli and Eric Nuermberger",
year = "2017",
month = "9",
day = "1",
doi = "10.1128/AAC.00913-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

AU - Li, Si Yang

AU - Tasneen, Rokeya

AU - Tyagi, Sandeep

AU - Soni, Heena

AU - Converse, Paul J.

AU - Mdluli, Khisimuzi

AU - Nuermberger, Eric

PY - 2017/9/1

Y1 - 2017/9/1

N2 - New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus PZA shortened the treatment duration necessary to prevent relapse by 2 to 3 months and 1 to 2 months, respectively, compared with the current first-line regimen, in a murine TB model. These 3-drug combinations are now being studied in clinical trials. Here, the 4-drug combination of BDQPMDMXFPZA was compared to its 3-drug component regimens and different treatment durations of PZA and MXF were explored, to identify the optimal regimens and treatment times and to estimate the likelihood of success against drug-resistant strains. BDQPMDMXFPZA rendered all mice relapse-free after 2 months of treatment. PZA administration could be discontinued after the first month of treatment without worsening outcomes, whereas the absence of MXF, PZA, or BDQ administration from the beginning necessitated approximately 0.5, 1, or 2 months, respectively, of additional treatment to attain the same outcome.

AB - New regimens based on 2 or more novel agents are sought to shorten or to simplify treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the novel combinations of bedaquiline (BDQ) plus pretomanid (PMD) plus pyrazinamide (PZA) and PMD plus moxifloxacin (MXF) plus PZA shortened the treatment duration necessary to prevent relapse by 2 to 3 months and 1 to 2 months, respectively, compared with the current first-line regimen, in a murine TB model. These 3-drug combinations are now being studied in clinical trials. Here, the 4-drug combination of BDQPMDMXFPZA was compared to its 3-drug component regimens and different treatment durations of PZA and MXF were explored, to identify the optimal regimens and treatment times and to estimate the likelihood of success against drug-resistant strains. BDQPMDMXFPZA rendered all mice relapse-free after 2 months of treatment. PZA administration could be discontinued after the first month of treatment without worsening outcomes, whereas the absence of MXF, PZA, or BDQ administration from the beginning necessitated approximately 0.5, 1, or 2 months, respectively, of additional treatment to attain the same outcome.

KW - Bedaquliine

KW - Mouse

KW - Moxifloxacin

KW - Mycobacterium tuberculosis

KW - Pretomanid

KW - Pyrazinamide

UR - http://www.scopus.com/inward/record.url?scp=85028317237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028317237&partnerID=8YFLogxK

U2 - 10.1128/AAC.00913-17

DO - 10.1128/AAC.00913-17

M3 - Article

C2 - 28630203

AN - SCOPUS:85028317237

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

M1 - e00913-17

ER -